Mark E. Robson

Oct 17, 2024 | nature.com | Nicholas Mai |Pedram Razavi |Anton Safonov |Chau Dang |Larry Norton |Mark E. Robson | +1 more

AbstractAfter disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines for estrogen receptor positive (ER+) metastatic breast cancer (MBC). CDK4/6i retrial as a treatment strategy is commonplace in modern clinical practice; however, the available prospective data investigating this strategy have had inconclusive results.

Sep 28, 2024 | belfasttelegraph.co.uk | Mark E. Robson

If you thought the Lions was difficult, the Bulls are likely to bring even more challenges in next Saturday’s second tour game for Ulster which will again be at altitude in Pretoria. And there could be some release of Springboks for Jake White coming too. Throw in that White has made it known he and the Bulls are hacked off at losing two URC Finals and it could be very tricky for Ulster.

Jan 3, 2024 | jamanetwork.com | Victoria Blinder |Mark E. Robson |Elena B. Elkin |Christina M. Zettler

Key PointsQuestion  Is adjuvant olaparib cost-effective in patients with early-stage breast cancer with high-risk disease and germline BRCA1/2 mutations?